MedTrace Logo

An Extension Study of ABT-806 in Subjects With Advanced Solid Tumors

NCT01406119 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2017-01-27

No results posted yet for this study

Summary

This is an extension study of ABT-806 for subjects with advanced solid tumors.

Conditions

Interventions

DRUG

ABT-806

ABT-806 will be administered by intravenous infusion.

Sponsors & Collaborators

  • AbbVie (prior sponsor, Abbott)

    lead INDUSTRY

Principal Investigators

  • Christopher Ocampo, MD · AbbVie

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2017-01-31
Completion
2017-01-31

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01406119 on ClinicalTrials.gov